{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T19:09:57Z","timestamp":1774465797070,"version":"3.50.1"},"reference-count":37,"publisher":"Georg Thieme Verlag KG","issue":"08","funder":[{"DOI":"10.13039\/100009045","name":"Jagiellonian University Medical College","doi-asserted-by":"crossref","award":["N41\/DBS\/000516"],"award-info":[{"award-number":["N41\/DBS\/000516"]}],"id":[{"id":"10.13039\/100009045","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Background\u2003Atrial fibrillation (AF) is associated with a prothrombotic state. Presence of active tissue factor (TF), activated factor IX (FIXa) and FXIa in circulating blood contributes to thrombosis. We investigated a prognostic value of these factors in AF patients.<\/jats:p><jats:p>Methods\u2003In this cohort study, 284 AF patients (aged 63.3\u2009\u00b1\u20098.8 years) treated with oral anticoagulants were enrolled. Plasma levels of active coagulation factors were evaluated using thrombin generation assay. Concentrations of fibrinogen, D-dimer, interleukin-6 (IL-6), and endothelial damage markers, including von Willebrand factor (VWF) and soluble (s)E-selectin, were also measured. Ischemic stroke and cardiovascular death, analyzed separately or as a composite endpoint, were recorded during a mean follow-up of 47 months.<\/jats:p><jats:p>Results\u2003Cerebrovascular events were observed in 20 patients (1.8%\/year) who had at baseline higher fibrinogen, D-dimer, and VWF levels. Active TF and FXIa at enrollment were detectable in 12 (60%) and 15 (75%) patients who experienced ischemic stroke during follow-up. The composite endpoint observed in 23 patients (2.1%\/year) was associated with increased concentrations of the above laboratory variables, along with 26% higher IL-6 levels. sE-selectin did not differ between the studied groups. On multivariable regression analysis, advanced age, anticoagulation discontinuation, and detectable FXIa, but not active TF, independently predicted the composite endpoint. No associations of FIXa with the study endpoints were observed.<\/jats:p><jats:p>Conclusion\u2003FXIa present in circulating blood is associated with increased risk of ischemic stroke and cardiovascular death in anticoagulated AF patients during long-term follow-up. FXIa inhibition could be useful in cardiovascular prevention in AF beyond the current oral anticoagulation.<\/jats:p>","DOI":"10.1055\/s-0042-1742366","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:38:20Z","timestamp":1644885500000},"page":"1397-1406","source":"Crossref","is-referenced-by-count":13,"title":["Active FXI Can Independently Predict Ischemic Stroke in Anticoagulated Atrial Fibrillation Patients: A Cohort Study"],"prefix":"10.1055","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1762-308X","authenticated-orcid":false,"given":"Micha\u0142 Tomasz","family":"Z\u0105bczyk","sequence":"first","affiliation":[{"name":"Department of Experimental Cardiac Surgery, Anesthesiology and Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland"},{"name":"Krakow Centre for Medical Research and Technologies, John Paul II Hospital, Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maksymilian","family":"Hanarz","sequence":"first","affiliation":[{"name":"Department of Experimental Cardiac Surgery, Anesthesiology and Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof P.","family":"Malinowski","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics and Telemedicine, Jagiellonian University Medical College, Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u017cbieta","family":"Pociask","sequence":"additional","affiliation":[{"name":"Department of Biocybernetics and Biomedical Engineering, AGH University of Science and Technology, Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saulius","family":"Butenas","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, University of Vermont, Burlington, Vermont, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Gajos","sequence":"additional","affiliation":[{"name":"Department of Coronary Disease and Heart Failure, John Paul II Hospital, Krakow, Poland"},{"name":"Department of Coronary Disease and Heart Failure, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0667-8109","authenticated-orcid":false,"given":"Anetta","family":"Undas","sequence":"additional","affiliation":[{"name":"Department of Experimental Cardiac Surgery, Anesthesiology and Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland"},{"name":"Krakow Centre for Medical Research and Technologies, John Paul II Hospital, Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"G Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"C T Ruff","year":"2014","journal-title":"Lancet"},{"issue":"05","key":"ref3","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.cjca.2019.01.014","article-title":"Prothrombotic state in atrial fibrillation patients with one additional risk factor of the CHA2DS2-VASc score (beyond sex)","volume":"35","author":"B G\u0142owicki","year":"2019","journal-title":"Can J Cardiol"},{"issue":"04","key":"ref4","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1378\/chest.07-1185","article-title":"Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate\/nitrite product as indices of endothelial damage\/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation","volume":"132","author":"B Freestone","year":"2007","journal-title":"Chest"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cvr\/cvy272","article-title":"The prothrombotic state in atrial fibrillation: pathophysiological and management implications","volume":"115","author":"A A Khan","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"e0124716","DOI":"10.1371\/journal.pone.0124716","article-title":"Association of hemostatic markers with atrial fibrillation: a meta-analysis and meta-regression","volume":"10","author":"N Wu","year":"2015","journal-title":"PLoS One"},{"issue":"02","key":"ref7","first-page":"185","article-title":"Altered fibrin clot properties and fibrinolysis in patients with atrial fibrillation: practical implications","volume":"22","author":"A Undas","year":"2020","journal-title":"Europace"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1161\/ATVBAHA.117.309846","article-title":"Tissue factor: an essential mediator of hemostasis and trigger of thrombosis","volume":"38","author":"S P Grover","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"05","key":"ref9","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/j.thromres.2011.06.010","article-title":"Circulating activated factor XI and active tissue factor as predictors of worse prognosis in patients following ischemic cerebrovascular events","volume":"128","author":"A Undas","year":"2011","journal-title":"Thromb Res"},{"issue":"05","key":"ref10","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.5114\/aoms.2015.54791","article-title":"Activated factor IX, factor XI and tissue factor identify patients with permanent atrial fibrillation treated with warfarin who are at risk of ischemic stroke","volume":"12","author":"P Kusak","year":"2016","journal-title":"Arch Med Sci"},{"issue":"21","key":"ref11","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"A J Camm","year":"2012","journal-title":"Eur Heart J"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1046\/j.1538-7836.2003.00431.x","article-title":"The function of factor XI in tissue factor-initiated thrombin generation","volume":"1","author":"S Butenas","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"08","key":"ref13","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1111\/j.1538-7836.2006.02000.x","article-title":"Immunologic quantitation of tissue factors","volume":"4","author":"B Parhami-Seren","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"S Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1160\/TH07-08-0499","article-title":"Factor XIa and tissue factor activity in patients with coronary artery disease","volume":"99","author":"S Butenas","year":"2008","journal-title":"Thromb Haemost"},{"issue":"08","key":"ref16","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2016-06-722298","article-title":"In vitro activation of coagulation by human neutrophil DNA and histone proteins but not neutrophil extracellular traps","volume":"129","author":"D F Noubouossie","year":"2017","journal-title":"Blood"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1111\/jth.15486","article-title":"Associations of coagulation factor X and XI with incident acute coronary syndrome and stroke: a nested case-control study","volume":"19","author":"H Chen","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1111\/jth.15092","article-title":"Coagulation factor XII, XI, and VIII activity levels and secondary events after first ischemic stroke","volume":"18","author":"J L Rohmann","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1309\/QC259F09UNMKVP0R","article-title":"Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events","volume":"126","author":"D T Yang","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1477-9560-7-11","article-title":"Plasma TF activity predicts cardiovascular mortality in patients with acute myocardial infarction","volume":"7","author":"B A Steppich","year":"2009","journal-title":"Thromb J"},{"issue":"09","key":"ref21","doi-asserted-by":"crossref","first-page":"334","DOI":"10.20452\/pamw.961","article-title":"Active tissue factor and activated factor XI in circulating blood of patients with systolic heart failure due to ischemic cardiomyopathy","volume":"120","author":"M Zabczyk","year":"2010","journal-title":"Pol Arch Med Wewn"},{"issue":"10","key":"ref22","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1056\/NEJM200003093421004","article-title":"High levels of coagulation factor XI as a risk factor for venous thrombosis","volume":"342","author":"J C Meijers","year":"2000","journal-title":"N Engl J Med"},{"issue":"02","key":"ref23","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.thromres.2009.06.033","article-title":"Cardiovascular complications of diabetes mellitus: the tissue factor perspective","volume":"125","author":"V Y Bogdanov","year":"2010","journal-title":"Thromb Res"},{"issue":"03","key":"ref24","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/MBC.0b013e32834ee194","article-title":"Factors associated with the presence of circulating active tissue factor and activated factor XI in stable angina patients","volume":"23","author":"M Z\u0105bczyk","year":"2012","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"25","key":"ref25","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1016\/j.jacc.2018.06.082","article-title":"Clinician's guide to reducing inflammation to reduce atherothrombotic risk: JACC review topic of the week","volume":"72","author":"P M Ridker","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"ref26","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1161\/01.CIR.0000033220.97592.9A","article-title":"Plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors","volume":"106","author":"D S Conway","year":"2002","journal-title":"Circulation"},{"issue":"25","key":"ref27","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.jacc.2010.12.033","article-title":"Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients","volume":"57","author":"V Rold\u00e1n","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"ref28","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/eci.12140","article-title":"Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a \u2018real-world\u2019 community cohort of patients with atrial fibrillation","volume":"43","author":"S Krishnamoorthy","year":"2013","journal-title":"Eur J Clin Invest"},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/13543784.2021.1897786","article-title":"Drugs in phase I and II clinical development for the prevention of stroke in patients with atrial fibrillation","volume":"30","author":"R Bentley","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"issue":"06","key":"ref30","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1055\/s-0040-1710013","article-title":"Role of factor XIa and plasma kallikrein in arterial and venous thrombosis","volume":"120","author":"M Visser","year":"2020","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1055\/s-0035-1546466","article-title":"Next generation antithrombotic therapy: focus on antisense therapy against coagulation factor XI","volume":"41","author":"G Lippi","year":"2015","journal-title":"Semin Thromb Hemost"},{"issue":"07","key":"ref32","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"P Verhamme","year":"2021","journal-title":"N Engl J Med"},{"issue":"02","key":"ref33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"J I Weitz","year":"2020","journal-title":"JAMA"},{"issue":"03","key":"ref34","doi-asserted-by":"crossref","first-page":"e022478","DOI":"10.1136\/bmjopen-2018-022478","article-title":"Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)","volume":"9","author":"M Rohla","year":"2019","journal-title":"BMJ Open"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejim.2018.05.016","article-title":"Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: a comparison between EORP-AF pilot and EHS-AF registries","volume":"55","author":"M Proietti","year":"2018","journal-title":"Eur J Intern Med"},{"issue":"10","key":"ref36","first-page":"878","article-title":"Oral anticoagulation in patients with active cancer and atrial fibrillation: current challenges","volume":"130","author":"M Sorigue","year":"2020","journal-title":"Pol Arch Intern Med"},{"issue":"11","key":"ref37","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1161\/STROKEAHA.119.026545","article-title":"Leveraging human genetics to estimate clinical risk reductions achievable by inhibiting factor XI","volume":"50","author":"B Georgi","year":"2019","journal-title":"Stroke"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1742366.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T15:09:02Z","timestamp":1726672142000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1742366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":37,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2022,8,21]]},"published-print":{"date-parts":[[2022,8]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1742366","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]}}}